Cite
HARVARD Citation
Gonem, S. et al. (2016). Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet. 4 (9), pp. 699-707. [Online].